Corley Jesse Anderson Buys 37,037 Shares of RxSight, Inc.
On June 17, 2026, Corley Jesse Anderson acquired 37,037 shares of RxSight, Inc. (RXST).
Key Points
- Corley Jesse Anderson bought 37,037 shares of RxSight, Inc. on June 17, 2026, with shares trading around $4.73.
- RxSight, Inc. has a market cap of about $195.8 million and a 52-week range between $4.48 and $14.29.
- Analysts like Needham maintain a 'buy' rating with a target price of $11.00 for RxSight, Inc.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Corley Jesse Anderson purchased 37,037 shares of RxSight, Inc. (NasdaqGM: RXST). The shares were acquired without a pre-planned trading arrangement, adding to the insider activity at the medical device company. Shares of RxSight traded around $4.73 at the time.
Other Institutional Activity in RxSight, Inc.
Institutional investors have been active in RxSight, Inc. recently. BlackRock, Inc. increased its holdings by 482,086 shares, bringing its total to about 3,187,092 shares valued at approximately $19.63 million. Meanwhile, Millennium Management LLC reduced its position by 69,579 shares, leaving it with 2,059,459 shares valued at $12.69 million. Artisan Partners Limited Partnership also cut its stake by 98,580 shares, holding 2,058,684 shares worth about $12.68 million. Nomura Holdings Inc. maintained its position with 2,000,060 shares valued at $12.32 million, while No Street GP LP added 25,000 shares, ending with 2,000,000 shares valued at $12.32 million.
RxSight, Inc. Stock Down 32.9%
Shares of RxSight, Inc. (NasdaqGM: RXST) are trading near $4.73. The company has a market capitalization of approximately $195.8 million. Its forward P/E ratio is not meaningful as the company is not currently profitable. The stock has a 52-week low of $4.48 and a high of $14.29, with a 50-day moving average of $6.09 and a 200-day moving average of $8.36. RxSight has a current ratio of 10.2 and a quick ratio of 8.779, indicating strong liquidity, but a debt-to-equity ratio of 4.05.
$RXST stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
RxSight, Inc. reported revenue of $127.5 million, though it saw a revenue decline of 18.5%. The company posted a net margin of -36.6% and a return on equity of -17.1%. The next earnings report is scheduled for August 6, 2026.
Insider Buying and Selling at RxSight, Inc.
On June 17, 2026, several insiders, including Tammenoms Bakker Juliet, Warner Robert Keith, Palmisano Robert, Link William PhD, Maniar Shweta, and Corley Jesse Anderson, each bought 37,037 shares. These purchases were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On May 7, 2026, Wells Fargo maintained a 'hold' rating with a $9.00 price target for RxSight, Inc. Needham maintained a 'buy' rating with an $11.00 target on the same date. Overall, the consensus among analysts is neutral with an average target price of $8.79.
About RxSight, Inc.
RxSight, Inc. is a healthcare company based in Aliso Viejo, California, specializing in medical devices. It focuses on developing and selling light adjustable intraocular lenses used in cataract surgery. The company's flagship product, the RxSight system, allows doctors to adjust and enhance patients' vision post-surgery. The system includes a light adjustable lens and a light delivery device. Dr. Ronald M. Kurtz serves as the CEO, and the company employs 461 people.
Bottom Line
Corley Jesse Anderson's recent purchase of RxSight, Inc. shares adds to the insider activity at the company. Investors keep an eye on such transactions for insights into potential company performance. It's important to remember that insider transactions are reported after the fact and don't necessarily indicate future stock performance.
Get RxSight, Inc. alerts
New 13F filings, insider trades, and analyst moves on $RXST, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.